Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GLS | O94925 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 4/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852622 | 0.88 | GLS (0.57) | ALDH1A1MEN1KMT2ALMNAGLS | |
| SCHEMBL13962893 | 0.88 | GLS (0.55) | ALDH1A1MEN1KMT2ALMNAGLS | |
| SCHEMBL23532330 | 0.88 | MEN1 (0.54) | ALDH1A1MEN1KMT2ALMNAGLS | |
| SCHEMBL25083480 | 0.88 | MEN1 (0.54) | ALDH1A1MEN1KMT2ALMNAGLS | |
| SCHEMBL20455806 | 0.85 | GLS (0.60) | ALDH1A1MEN1KMT2ALMNAGLS | |
| SCHEMBL23542060 | 0.84 | GLS (0.57) | ALDH1A1MEN1KMT2ALMNAGLS | |
| SCHEMBL6488674 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ALMNAOPRM1 | |
| SCHEMBL12592927 | 0.84 | MAPT (0.47) | ALDH1A1MEN1KMT2ALMNAGLS | |
| SCHEMBL10112780 | 0.83 | MEN1 (0.48) | ALDH1A1MEN1KMT2ALMNAGLS | |
| SCHEMBL6641491 | 0.82 | KMT2A (0.69) | ALDH1A1MEN1KMT2ALMNAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4159727-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-20040116699-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-06-17 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ALDH1A1 1534/4885MEN1 3154/4885KMT2A 3926/4885 |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | ALDH1A1 4060/4885MEN1 3277/4885KMT2A 1618/4885 |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ALDH1A1 1534/4885MEN1 3154/4885KMT2A 3926/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | ALDH1A1 2417/4885MEN1 3539/4885KMT2A 4109/4885 |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | ALDH1A1 208/4885MEN1 2632/4885KMT2A 4688/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ALDH1A1 1727/4885MEN1 3362/4885KMT2A 4013/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | ALDH1A1 264/4885MEN1 3042/4885KMT2A 4622/4885 |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ALDH1A1 1727/4885MEN1 3362/4885KMT2A 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.